XSTO
ONCOZ
Market cap6mUSD
May 30, Last price
5.36SEK
1D
6.56%
1Q
-14.10%
IPO
-60.37%
Name
Oncozenge AB
Chart & Performance
P/E
—
P/S
62,782.75
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
1k
-66.67%
Net income
-9m
L-45.37%
CFO
-9m
L-48.70%
Profile
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | 1,000 -66.67% | 3 | |||
Cost of revenue | 1,719 | 43,567 | |||
Unusual Expense (Income) | |||||
NOPBT | (1,718) | 3 | (43,567) | ||
NOPBT Margin | 100.00% | ||||
Operating Taxes | 3,077 | ||||
Tax Rate | |||||
NOPAT | (1,718) | 3 | (46,644) | ||
Net income | (8,688) -45.37% | (15,902) -65.91% | (46,646) 1,100.36% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 570 | ||||
BB yield | -1.57% | ||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 1,645 | ||||
Net debt | (3,863) | (12,627) | (29,140) | ||
| Cash flow | |||||
Cash from operating activities | (8,764) | (17,083) | (22,078) | ||
CAPEX | |||||
Cash from investing activities | 570 | ||||
Cash from financing activities | |||||
FCF | (1,718) | 3 | (46,644) | ||
| Balance | |||||
Cash | 3,863 | 12,627 | 29,140 | ||
Long term investments | |||||
Excess cash | 3,863 | 12,627 | 29,140 | ||
Stockholders' equity | (74,460) | (65,769) | (49,867) | ||
Invested Capital | 84,410 | 84,410 | 83,656 | ||
ROIC | 0.00% | ||||
ROCE | 0.02% | ||||
| EV | |||||
Common stock shares outstanding | 11,713 | 11,713 | 11,713 | ||
Price | 3.75 21.36% | 3.09 -43.82% | 5.50 -52.42% | ||
Market cap | 43,925 21.36% | 36,194 -43.82% | 64,423 -52.42% | ||
EV | 40,062 | 23,567 | 35,283 | ||
EBITDA | (1,718) | 3 | (20,399) | ||
EV/EBITDA | 7,855.64 | ||||
Interest | |||||
Interest/NOPBT | |||||